Single User License
INR 129000
Site License
INR 258000
Corporate User License
INR 387000

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Left Ventricular Dysfunction-Pipeline Review, H2 2015

Left Ventricular Dysfunction-Pipeline Review, H2 2015


  • Products Id :- GMDHC7020IDB
  • |
  • Pages: 62
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Left Ventricular Dysfunction-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Left Ventricular Dysfunction-Pipeline Review, H2 2015', provides an overview of the Left Ventricular Dysfunction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Left Ventricular Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Left Ventricular Dysfunction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Left Ventricular Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Left Ventricular Dysfunction Overview 6

Therapeutics Development 7

Pipeline Products for Left Ventricular Dysfunction-Overview 7

Pipeline Products for Left Ventricular Dysfunction-Comparative Analysis 8

Left Ventricular Dysfunction-Therapeutics under Development by Companies 9

Left Ventricular Dysfunction-Therapeutics under Investigation by Universities/Institutes 10

Left Ventricular Dysfunction-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Left Ventricular Dysfunction-Products under Development by Companies 14

Left Ventricular Dysfunction-Products under Investigation by Universities/Institutes 15

Left Ventricular Dysfunction-Companies Involved in Therapeutics Development 16

Acorda Therapeutics, Inc. 16

Amgen Inc. 17

Bayer AG 18

Innopharmax Inc. 19

RedHill Biopharma Ltd. 20

TiGenix NV 21

Left Ventricular Dysfunction-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

BAY-1142524-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

CAP-1001-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

CAP-1002-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

carvedilol CR-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

carvedilol CR-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

cimaglermin alfa-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

CTX-101-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

omecamtiv mecarbil-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecule to Target O2 Radical for Left Ventricular Dysfunction and Diabetic Complications-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Left Ventricular Dysfunction-Recent Pipeline Updates 45

Left Ventricular Dysfunction-Dormant Projects 55

Left Ventricular Dysfunction-Discontinued Products 56

Left Ventricular Dysfunction-Product Development Milestones 57

Featured News & Press Releases 57

Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013 57

Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013 58

Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

Number of Products under Development for Left Ventricular Dysfunction, H2 2015 7

Number of Products under Development for Left Ventricular Dysfunction-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Number of Products under Investigation by Universities/Institutes, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Products under Investigation by Universities/Institutes, H2 2015 15

Left Ventricular Dysfunction-Pipeline by Acorda Therapeutics, Inc., H2 2015 16

Left Ventricular Dysfunction-Pipeline by Amgen Inc., H2 2015 17

Left Ventricular Dysfunction-Pipeline by Bayer AG, H2 2015 18

Left Ventricular Dysfunction-Pipeline by Innopharmax Inc., H2 2015 19

Left Ventricular Dysfunction-Pipeline by RedHill Biopharma Ltd., H2 2015 20

Left Ventricular Dysfunction-Pipeline by TiGenix NV, H2 2015 21

Assessment by Monotherapy Products, H2 2015 22

Number of Products by Stage and Target, H2 2015 24

Number of Products by Stage and Mechanism of Action, H2 2015 26

Number of Products by Stage and Route of Administration, H2 2015 28

Number of Products by Stage and Molecule Type, H2 2015 30

Left Ventricular Dysfunction Therapeutics-Recent Pipeline Updates, H2 2015 45

Left Ventricular Dysfunction-Dormant Projects, H2 2015 55

Left Ventricular Dysfunction-Discontinued Products, H2 2015 56

List of Figures

Number of Products under Development for Left Ventricular Dysfunction, H2 2015 7

Number of Products under Development for Left Ventricular Dysfunction-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 22

Number of Products by Top 10 Targets, H2 2015 23

Number of Products by Stage and Top 10 Targets, H2 2015 23

Number of Products by Top 10 Mechanism of Actions, H2 2015 25

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 25

Number of Products by Top 10 Routes of Administration, H2 2015 27

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 27

Number of Products by Top 10 Molecule Types, H2 2015 29

Number of Products by Stage and Top 10 Molecule Types, H2 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acorda Therapeutics, Inc.

Amgen Inc.

Bayer AG

Innopharmax Inc.

RedHill Biopharma Ltd.

TiGenix NV

Left Ventricular Dysfunction Therapeutic Products under Development, Key Players in Left Ventricular Dysfunction Therapeutics, Left Ventricular Dysfunction Pipeline Overview, Left Ventricular Dysfunction Pipeline, Left Ventricular Dysfunction Pipeline Assessment


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com